Substudy 3 will evaluate preliminary anti-tumor activity of AZD0901 monotherapy in patients with CLDN18.2-positive advanced or metastatic BTCs with ≤2 prior lines of therapy. This evidence concerns the gene CLDN18 and neoplasm.